Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rather paltry number of shares traded after hours. I usually see a lot more.
So what happens with call options when GALE becomes part of SLS?
Anything you can share?
If PETX gets approval or a new trial starts, we would certainly hear about that. There are a number of catalysts I also expect to be PR'd by year's end if the corporate presentation's timeline is accurate. Like many others here, though, I wonder about the silence.
I would really like to see an update for slide #31 (Brown study) in the corporate presentation. The results are as of 12/9/16. I hope many of them are still relapse free.
Hmm...I wonder from where he gets his money...
Picked up 25 calls at 10, myself.
Thanks for the link. Great read!
Your check must have been short.
We've seen good news at conferences before without doing much for the PPS. I'm cautiously optimistic that this time may be different. I think we'll see many M&As from now to next year and, even if Advaxis does not get picked up, I think the expectation that it could happen, along with good results and met milestones, will help us back to double digits.
I was told the same thing by IR when the GOG trial page was showing an older status.
Thanks. I checked Fintel, too. The recent sells from Broadfin and Sectoral Asset may have brought the numbers down.
Well, a little more than a month to report on over half of those milestones. I'm really interested in the TNBC data. Could be the game changer. Possibly, at some point, eligible for AA.
Traderbx, where are you getting the numbers for institutional ownership? Thanks.
"Two poster presentations will feature preliminary immune correlative data from the ADXS-PSA monotherapy treatment arm of Advaxis’ Phase 1/2 study in combination with KEYTRUDA® (pembrolizumab) in metastatic castration-resistant prostate cancer (mCRPC) patients. The third presentation will feature preclinical data with the company’s HPV-targeted immunotherapy, axalimogene filolisbac."
NEO shows on-going now on slide 9. Can't recall if it was in planned status on the last deck.
Thanks. That was excellent!
James, I had been thinking along the same lines. There has been much speculation and inference of some kind of misdeed but, as he didn't see it coming, I formed the same thought as you have stated. I'd wondered if some of the large holders put pressure on the board to replace him with someone who would willing to make deals now. Just my opinion.
Could Noelle answer this?
Well, who knows what will happen but it does sound to me that the company is gearing up to get the manufacturing plant up and running. They appear to be highly confident they will get EU approval. (Spoiler alert, it may not occur.)
If you haven't reviewed this upload on canine osteosarcoma, it's worth a read. It appears they learned a lot and can possibly improve effectiveness. I think this was touched on at the infamous Investor Day (can't really recall).
https://www.advaxis.com/wp-content/uploads/2017/06/Lm-LLO-Immunotherapy-plus-Radiation-Delays-Tumor-Progression-and-Prolongs-Survival-in-Osteosarcoma-1.pdf
My thoughts exactly.
When Greg Mayes departed Advaxis, rumors abounded. Some questioned his reason for leaving even after he explained it. Well, here's the truth for those who doubted:
https://www.statnews.com/2017/08/17/biopharma-executive-fund-epilepsy/
Here's what I really am intrigued by, "The third poster presentation, "Identification of an intratumoral immune gene signature associated with tumor regression in an axalimogene filolisbac-treated murine HPV+ tumor model,” will include preclinical data regarding molecular biomarkers associated with tumor regression in a murine HPV+ tumor model. It will be presented by Rachelle Kosoff, Ph.D., Senior Scientist in Research at Advaxis."
“Our findings provide important insights into identifying those patients who are benefiting from these treatments,” said Dr. Hayes. “We’re pleased to share our findings with the rest of the community at the International Cancer Immunotherapy Conference as we continue our work to bring new treatment options to patients.”
If this helps make an already efficacious treatment better by predicting (hopefully) who may respond, think of the added benefit and value!
Well, technically, if the decision was put to him to be fired or resign, and he chose to resign, she could be right. She's pretty accessible by phone so you may want to call her and get the lowdown for yourself. I do know that one of the reasons she came to Advaxis was because she believed in Dan. I can't think that she was too happy with what happened.
It was during the clinical hold. When the hold was lifted, I contacted IR who told me it was GOG's responsibility to update that particular trial. Guess they fell a tad behind...until now. Check the history of changes to see what it went through.
Thanks, exel.
exel, can you elaborate a bit? I assume you talked with Noelle. I did not ask her about an EU partnership during our last conversation but am very curious on what you "picked up on" when you communicated her with. Thanks in advance.
Thanks, excellent read!
His Linked In page still shows him there so either it was very recent or maybe they moved him around.
I think, based on his bio, he's an excellent choice. Down to three open positions on the job listings page.
Seems like a good fit for the position.
I guess you didn't fully read my previous post. The shorts and tutes opinions are of no interest to me. If you're so concerned ADXL doesn't work, contact the trial investigators and tell them what the shorts and tutes think. Let us know what they say.
Again, you are certainly entitled to your opinion as I am to mine.
I don't care what shorts and tutes believe. Until they can disprove these comments below, I believe it works:
“The 12-month survival rate of axalimogene filolisbac reached unprecedented levels in this study, which is both impressive and important given the lack of innovation
in metastatic cervical cancer.”
Warner K. Huh, MD
Director, Division of
Gynecologic Oncology
University of Alabama, Birmingham
Lead Investigator of GOG-0265 Study
That is your opinion.
Or, if you're an intelligent person, you can choose to believe in the science as borne out by clinical trial results and a number of complete responses and the interest and support of partners and trial investigators.
"but the silence has been planned..." Hmm...could mean several things. If this is from Noelle, she's pretty good at responding in a timely manner. I talked to her yesterday about the CEO search. Still on-going.
This should be a very interesting poster:
The third poster presentation, “Identification of an intratumoral immune gene signature associated with tumor regression in an axalimogene filolisbac-treated murine HPV+ tumor model,” will include preclinical data regarding molecular biomarkers associated with tumor regression in a murine HPV+ tumor model. It will be presented by Rachelle Kosoff, Ph.D., Senior Scientist in Research at Advaxis.
“Our findings provide important insights into identifying those patients who are benefiting from these treatments,” said Dr. Hayes. “We’re pleased to share our findings with the rest of the community at the International Cancer Immunotherapy Conference as we continue our work to bring new treatment options to patients.”
If AXAL can be made even more effective by helping to predict who may benefit from the treatment, that bodes extremely well for patients and for designing trials.
Well, either way, I'm still hopeful it will happen.